BioNTech at World Vaccine Congress Europe 2026
Oct 19–21, 2026 Amsterdam, Netherlands ~2k attendees Website
BioNTech takes part in 3 sessions at World Vaccine Congress Europe 2026 in Amsterdam. Its sessions span cancer and infectious disease, from regulatory hurdles for multi-modality cancer immunotherapy to balancing speed and safety in global vaccine access. The most concrete covers the design and development of mRNA-encoded tuberculosis vaccines.
| Organization | World Vaccine Congress Europe 2026 Attendance |
|---|---|
BioNTech Mainz, Germany | |
Develops mRNA vaccines and immunotherapies for infectious diseases and cancer, including the marketed COVID-19 vaccine Comirnaty. | Talk Mon Oct 19 10:15 Talk Mon Oct 19 15:00 Panel: Global Vaccine Access: Balancing Speed and Safety How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks. Talk Wed Oct 21 12:30 |
Instantly find 20 buyers from BioNTech
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Terrapinn or the World Vaccine Congress. Submit a correction